Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

intervet hellas ae (0000001815) Αγ. Δημητρίου 63,,174 56,174 56, Αλιμος,gr - avian infectious bronchitis virus strain d274 clone; inactivated newcastle disease strain clone 30; inactivated infectious bronchitis virus mass 41 strain at least - ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ - - - avian infectious bronchitis virus strain d274 clone 0,00 em.inj -; inactivated newcastle disease strain clone 30 50,00 em.inj -; inactivated infectious bronchitis virus mass 41 strain at least 0,00 em.inj - - avian infectious bronchitis virus + newcastle disease virus / paramyxovirus - Όρνιθες - Χρόνοι αναμονής: Όρνιθες 0 Ημέρες Κρέας και εδώδιμοι ιστοί; Όρνιθες 0 Ημέρες Αυγά

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ceva ΕΛΛΑΣ ΕΠΕ (0000003126) Εθνάρχου Μακαρίου 34,16341,Ηλιούπολη,gr - paromomycin ΘΕΙΙΚΌ ΆΛΑΣ - ΔΙΑΛΥΜΑ ΓΙΑ ΧΟΡΗΓΗΣΗ ΜΕ ΠΟΣΙΜΟ ΝΕΡΟ/ΓΑΛΑ - 140 mg/ml - paromomycin sulfate 200,00 sol.wa.mil 140 mg/ml - paromomycin - Βοοειδή; Χοίροι - Χρόνοι αναμονής: Βοοειδή 20 Ημέρες Κρέας και εδώδιμοι ιστοί; Χοίροι 3 Ημέρες Κρέας και εδώδιμοι ιστοί; Βοοειδή 110 Ημέρες Κρέας και εδώδιμοι ιστοί

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - Αντινεοπλασματικοί παράγοντες - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Αντινεοπλασματικοί παράγοντες - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Ανοσοδιεγερτικά, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

teva gmbh - φουμαρικό διμεθύλιο - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - φουμαρικό διμεθύλιο - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 και 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.